Scientists at Johns Hopkins Medicine say that an experimental monoclonal antibody drug called mAb43 appears to prevent and ...

CVS is getting into the business of making copycat biologic drugs, known as biosimilars, to profit directly from blockbusters ...

A $4.9 billion hole has appeared in Gilead’s pipeline. After years of setbacks, the big biotech dealt a final blow to its ...

Scientists say that an experimental monoclonal antibody drug called mAb43 appears to prevent and reverse the onset of clinical type 1 diabetes in mice, and in some cases, to lengthen the animals' ...

Today in the New England Journal of Medicine a study demonstrates that a single subcutaneous (just-under-the-skin) injection ...

One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in ...

Prasinezumab, an experimental monoclonal antibody treatment, may help reduce the deterioration of motor skills in people with ...

A recent study in Nature Medicine evaluated the efficacy of prasinezumab, a monoclonal antibody, in slowing the progression ...

A new study reports a single dose of a malaria antibody was 77% effective in protecting children in Mali from malaria, ...

SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other ...

International trial suggests prasinezumab, a monoclonal antibody, may reduce motor decline in patients with rapidly ...

Sanofi’s global collaboration with IGM Biosciences has shrunk by half. The companies will now focus only on developing three ...